SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: TAR-200 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer: Results from SunRISe-1 study